AUSTIN, Texas, July 18 /PRNewswire-FirstCall/ -- Introgen Therapeutics, Inc. will conduct a conference call today at 4:30 p.m. ET to discuss data regarding Introgen’s lead product ADVEXIN(R) presented at the annual meetings of the American Society of Gene Therapy (ASGT) and the American Society of Clinical Oncology (ASCO). A panel of clinical experts will discuss the importance of prognostic indicators of ADVEXIN efficacy associated with high response rates, locoregional disease control and increased survival from Introgen’s ADVEXIN program.
Conference Call Information Date / Time: July 18, 2006 at 4:30 p.m. ET Participant Dial-in numbers: (877) 616-4476 U.S. and Canada (706) 679-7372 International
This call is also being web cast and can be accessed at Introgen’s web site at http://www.introgen.com . A web cast replay will be available at http://www.introgen.com .
The call will be hosted by David Nance, President and CEO, Robert E. Sobol, M.D., Introgen’s senior vice president, Medical and Scientific Affairs, and Max W. Talbott, Ph.D., Introgen’s senior vice president for Regulatory and Worldwide Commercial Development. They will be joined by several investigators with first hand experience using ADVEXIN in clinical trials. Scheduled to participate in the discussion are: Dr. John Nemunaitis, Executive Director of the Baylor College Mary Crowley Medical Research Center in Dallas; Dr. Neil Senzer, Scientific Director, Mary Crowley Medical Research Center in Dallas; Dr. John T. Hamm, Medical Director of the Louisville Oncology Research Program; and, Dr. W. Jarrard Goodwin, Director, Sylvester Comprehensive Cancer Center of the University of Miami.
The call will include detailed discussions of the significance and clinical application of biomarkers predictive of ADVEXIN efficacy. The identification of prognostic indicators of ADVEXIN activity complies with initiatives of regulatory agencies to identify biomarkers that can predict the patient populations most likely to benefit from a specific cancer therapy.
In blinded analyses performed by an independent testing laboratory, a molecular biomarker was identified that predicted patients most likely to benefit from ADVEXIN cancer therapy. This biomarker also identifies patients who are less likely to respond to standard cancer treatment. The predictive biomarkers correlated with statistically significant increases in survival, tumor response and loco-regional disease control following ADVEXIN therapy in clinical trials. The predictive use of biomarkers coincides with Food and Drug Administration as well as with National Cancer Institute initiatives on the use of biomarkers in the development of breakthrough cancer therapies.
In addition, Introgen will discuss the successful use of ADVEXIN for Li- Fraumeni Syndrome cancer, an inherited form of malignancy characterized by the loss of p53 tumor suppressor protection.
About Introgen Therapeutics, Inc.
Introgen Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted molecular therapies for the treatment of cancer and other diseases. Introgen is developing molecular therapeutics, immunotherapies, vaccines and nano-particle therapies to treat a wide range of cancers using tumor suppressors and cytokines. Introgen maintains integrated research, development, manufacturing, clinical and regulatory departments and operates multiple manufacturing facilities including a commercial scale cGMP manufacturing facility.
Statements in this release that are not strictly historical may be “forward-looking” statements, including those relating to Introgen’s future success with its ADVEXIN clinical development program for the treatment of cancer and other diseases. The actual results may differ from those described in this release due to risks and uncertainties that exist in Introgen’s operations and business environment, including Introgen’s stage of product development and the limited experience in the development of gene-based drugs in general, dependence upon proprietary technology and the current competitive environment, history of operating losses and accumulated deficits, reliance on collaborative relationships, and uncertainties related to clinical trials, the safety and efficacy of Introgen’s product candidates, the ability to obtain the appropriate regulatory approvals, Introgen’s patent protection and market acceptance, as well as other risks detailed from time to time in Introgen’s filings with the Securities and Exchange Commission including its filings on Form 10-K and Form 10-Q. Introgen undertakes no obligation to publicly release the results of any revisions to any forward-looking statements that reflect events or circumstances arising after the date hereof.
Editor’s Note: For more information on Introgen Therapeutics, or for a menu of archived press releases, please visit Introgen’s Website at: http://www.introgen.com.
Contact: Introgen Therapeutics, Inc. C. Channing Burke (512) 708 9310 Ext. 322 Email: c.burke@introgen.com
Introgen Therapeutics, Inc.
CONTACT: C. Channing Burke of Introgen Therapeutics, Inc.,+1-512-708-9310, ext. 322, or c.burke@introgen.com
